Antibiotic combinations for the empiric treatment of the febrile neutropenic patient

T. J. Walsh, S. C. Schimpff

Research output: Contribution to journalArticle

Abstract

Empiric antimicrobial therapy in the granulocytopenic patient has traditionally consisted of a combination of an aminoglycoside plus a cephalosporin or aminoglycoside plus an antipseudomonal penicillin. These combinations have been proven reasonably effective and only moderately toxic. In some centers trimethoprim-sulfamethoxazole combined with an aminoglycoside or anti-pseudomonal penicillin has been used, again with good efficacy and minimal toxicity. The newer extended spectrum penicillins and cephalosporins has made possible two-drug combinations with aminoglycosides that provide double coverage of nearly all of the common bacterial pathogens while concurrently providing synergy against most of these same organisms. Further, it is now possible to have a double beta-lactam combination of a penicillin and cephalosporin which has the advantages of broad spectrum by antimicrobials and, at times, synergistic activity but without the ototoxicity and nephrotoxicity of aminoglycosides. The double beta-lactam combination would be especially useful in the neutropenic patient with established renal insufficiency or a history of previous courses of aminoglycoside therapy. Care should be taken in choosing such a regimen, however, because some combinations demonstrate antagonism. There is increasing data to indicate that patients with profound (14 days) granulocytopenia and concurrent gram-negative bacteremia respond best if treated with two active, bactericidal antibiotics, preferably synergistic in action. The potential for synergistic activity of the drugs selected should be, therefore, carefully considered. The duration of therapy should be adjusted according to the severity of infection, the response of the infection to antimicrobial therapy, and rate of recovery of the patient's granulocyte count.

Original languageEnglish (US)
Pages (from-to)58-63
Number of pages6
JournalSchweizerische Medizinische Wochenschrift
Volume113
Issue numberSUPPL. 14
StatePublished - 1983
Externally publishedYes

Fingerprint

Aminoglycosides
Fever
Anti-Bacterial Agents
Penicillins
Cephalosporins
beta-Lactams
Therapeutics
Agranulocytosis
Poisons
Sulfamethoxazole Drug Combination Trimethoprim
Drug Combinations
Bacteremia
Infection
Granulocytes
Renal Insufficiency
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antibiotic combinations for the empiric treatment of the febrile neutropenic patient. / Walsh, T. J.; Schimpff, S. C.

In: Schweizerische Medizinische Wochenschrift, Vol. 113, No. SUPPL. 14, 1983, p. 58-63.

Research output: Contribution to journalArticle

@article{ffe76a1af322400d9a57d7cc10ea8f3b,
title = "Antibiotic combinations for the empiric treatment of the febrile neutropenic patient",
abstract = "Empiric antimicrobial therapy in the granulocytopenic patient has traditionally consisted of a combination of an aminoglycoside plus a cephalosporin or aminoglycoside plus an antipseudomonal penicillin. These combinations have been proven reasonably effective and only moderately toxic. In some centers trimethoprim-sulfamethoxazole combined with an aminoglycoside or anti-pseudomonal penicillin has been used, again with good efficacy and minimal toxicity. The newer extended spectrum penicillins and cephalosporins has made possible two-drug combinations with aminoglycosides that provide double coverage of nearly all of the common bacterial pathogens while concurrently providing synergy against most of these same organisms. Further, it is now possible to have a double beta-lactam combination of a penicillin and cephalosporin which has the advantages of broad spectrum by antimicrobials and, at times, synergistic activity but without the ototoxicity and nephrotoxicity of aminoglycosides. The double beta-lactam combination would be especially useful in the neutropenic patient with established renal insufficiency or a history of previous courses of aminoglycoside therapy. Care should be taken in choosing such a regimen, however, because some combinations demonstrate antagonism. There is increasing data to indicate that patients with profound (14 days) granulocytopenia and concurrent gram-negative bacteremia respond best if treated with two active, bactericidal antibiotics, preferably synergistic in action. The potential for synergistic activity of the drugs selected should be, therefore, carefully considered. The duration of therapy should be adjusted according to the severity of infection, the response of the infection to antimicrobial therapy, and rate of recovery of the patient's granulocyte count.",
author = "Walsh, {T. J.} and Schimpff, {S. C.}",
year = "1983",
language = "English (US)",
volume = "113",
pages = "58--63",
journal = "Schweizerische Medizinische Wochenschrift",
issn = "0036-7672",
publisher = "EMH Swiss Medical Publishers Ltd.",
number = "SUPPL. 14",

}

TY - JOUR

T1 - Antibiotic combinations for the empiric treatment of the febrile neutropenic patient

AU - Walsh, T. J.

AU - Schimpff, S. C.

PY - 1983

Y1 - 1983

N2 - Empiric antimicrobial therapy in the granulocytopenic patient has traditionally consisted of a combination of an aminoglycoside plus a cephalosporin or aminoglycoside plus an antipseudomonal penicillin. These combinations have been proven reasonably effective and only moderately toxic. In some centers trimethoprim-sulfamethoxazole combined with an aminoglycoside or anti-pseudomonal penicillin has been used, again with good efficacy and minimal toxicity. The newer extended spectrum penicillins and cephalosporins has made possible two-drug combinations with aminoglycosides that provide double coverage of nearly all of the common bacterial pathogens while concurrently providing synergy against most of these same organisms. Further, it is now possible to have a double beta-lactam combination of a penicillin and cephalosporin which has the advantages of broad spectrum by antimicrobials and, at times, synergistic activity but without the ototoxicity and nephrotoxicity of aminoglycosides. The double beta-lactam combination would be especially useful in the neutropenic patient with established renal insufficiency or a history of previous courses of aminoglycoside therapy. Care should be taken in choosing such a regimen, however, because some combinations demonstrate antagonism. There is increasing data to indicate that patients with profound (14 days) granulocytopenia and concurrent gram-negative bacteremia respond best if treated with two active, bactericidal antibiotics, preferably synergistic in action. The potential for synergistic activity of the drugs selected should be, therefore, carefully considered. The duration of therapy should be adjusted according to the severity of infection, the response of the infection to antimicrobial therapy, and rate of recovery of the patient's granulocyte count.

AB - Empiric antimicrobial therapy in the granulocytopenic patient has traditionally consisted of a combination of an aminoglycoside plus a cephalosporin or aminoglycoside plus an antipseudomonal penicillin. These combinations have been proven reasonably effective and only moderately toxic. In some centers trimethoprim-sulfamethoxazole combined with an aminoglycoside or anti-pseudomonal penicillin has been used, again with good efficacy and minimal toxicity. The newer extended spectrum penicillins and cephalosporins has made possible two-drug combinations with aminoglycosides that provide double coverage of nearly all of the common bacterial pathogens while concurrently providing synergy against most of these same organisms. Further, it is now possible to have a double beta-lactam combination of a penicillin and cephalosporin which has the advantages of broad spectrum by antimicrobials and, at times, synergistic activity but without the ototoxicity and nephrotoxicity of aminoglycosides. The double beta-lactam combination would be especially useful in the neutropenic patient with established renal insufficiency or a history of previous courses of aminoglycoside therapy. Care should be taken in choosing such a regimen, however, because some combinations demonstrate antagonism. There is increasing data to indicate that patients with profound (14 days) granulocytopenia and concurrent gram-negative bacteremia respond best if treated with two active, bactericidal antibiotics, preferably synergistic in action. The potential for synergistic activity of the drugs selected should be, therefore, carefully considered. The duration of therapy should be adjusted according to the severity of infection, the response of the infection to antimicrobial therapy, and rate of recovery of the patient's granulocyte count.

UR - http://www.scopus.com/inward/record.url?scp=0020992521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020992521&partnerID=8YFLogxK

M3 - Article

C2 - 6361993

AN - SCOPUS:0020992521

VL - 113

SP - 58

EP - 63

JO - Schweizerische Medizinische Wochenschrift

JF - Schweizerische Medizinische Wochenschrift

SN - 0036-7672

IS - SUPPL. 14

ER -